EVO

#2028
Evotec SE - American Depositary Shares each representing 1/2 of
3.0 7 USD
+3.72%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
3.07
3.07
년간 변동
2.31
4.27
일일 변동
+3.72%
월간 변동
+3.02%
6달 변화
-7.25%
년간 변동율
-28.10%
이전 종가
2.9 6
Open
3.0 7
저가
3.0 7
High
3.0 7
양
1
전체 차트 열기 Full chart

Financials

개요 성명 통계 배당금
4분기 연간
손익계산서 대차대조표 현금 흐름
값 20212022202320242025 TTM

Evotec SE - American Depositary Shares each representing 1/2 of

Evotec SE is a publicly listed drug discovery and development company headquartered in Hamburg, Germany. The company operates globally, largely through external alliances with pharmaceutical and biotechnology companies, academic institutions, patient advocacy groups, and venture capitalists. As of 31 December 2021 Evotec had a market capitalization of €7.5 billion and a pipeline of more than 130 partnered programs in discovery, pre-clinical development and clinical development. The company's 4,200+ employees work across a number of therapeutic areas including CNS/neurology, metabolic diseases, Cancer, and inflammatory and infectious diseases. It has long-term discovery alliances with Bristol Myers Squibb, Bayer, Sanofi, Boehringer Ingelheim, the CHDI Foundation, Lilly, Takeda, Sernova, and more. On 28 October 2009 the company was listed on the TecDAX index, which tracks the performance of the 30 largest German companies from the technology sector. On 24 September 2018 Evotec joined the MDAX index, following a rule change that enabled dual listing. The MDAX tracks 60 Prime Standard shares from sectors excluding technology.

뉴스